Effects of different statins application methods on plaques in patients with coronary atherosclerosis

paythelady.612 shared this article with you from Inoreader Effects of different statins application methods on plaques in patients with coronary atherosclerosis Μέσω pubmed: "world j clin cases"... World J Clin Cases. 2021 Feb 6;9(4):812-821. doi: 10.12998/wjcc.v9.i4.812. ABSTRACT BACKGROUND: Discontinued application of statins may be related to adverse cardiovascular events. However, it is unclear whether different statins administration methods have effects on coronary artery plaques. AIM: To evaluate the effects of different statins application methods on plaques in patients with coronary atherosclerosis. METHODS: A total of 100 patients diagnosed with atherosclerotic plaque by coronary artery computed tomography were continuously selected and divided into three groups according to different statins administration methods (discontinued application group, n = 32; intermittent application group, n = 39; sustained application group, n = 29). The effects of the different statins application methods on coronary atherosclerotic plaque were assessed. RESULTS: The volume change and rate of change of the most severe plaques were significantly reduced in the sustained application group (P ≤ 0.001). The volume change of the most severe plaques correlated positively with low-density lipoprotein (LDL-C) levels only in the sustained application group (R = 0.362, P = 0.013). There were no changes in plaques or LDL-C levels in the intermittent and discontinued application groups. CONCLUSION: Continuous application of statins is effective for controlling plaque progression, whereas discontinued or intermittent administration of statins is not conducive to controlling plaques. Only with continuous statins administration can a reduction in LDL-C levels result in plaque volume shrinkage. PMID:33585627 | PMC:PMC7852639 | DOI:10.12998/wjcc.v9.i4.812 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.